Monica E. Loghin, M. D.

Peer-Reviewed Articles

1. Yeboa, DN, Whitfield, BT, Lin, R, Ejezie, CL, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, Harrison, R, Majd, NK, Puduvalli, VK, Aaroe, AE, Loghin, ME, O'Brien, BJ, Patel, AD, Patel, C, Wefel, JS, Taslicay, CA, Gule-Monroe, MK, Paulino, AC, McAleer, MF, Grosshans, DR, Ghia, AJ, Jiang, W, Chung, C, Maor, MM, Yang, CH, Gubbiotti, M, Kamiya Matsuoka, C, Ballester, L, Weathers, S, Huse, J. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses. Journal of neuro-oncology 176(1), 2026. e-Pub 2026. PMID: 41191157.
2. Weathers, S, Li, X, Zhu, H, Damania, A, Knafl, M, McKinley, BA, Lin, Y, Harrison, R, Majd, NK, O’Brien, BJ, Penas-Prado, M, Loghin, ME, Kamiya-Matsuoka, C, Yung, WA, Solis Soto, LM, Maru, DM, Wistuba, II, Parra Cuentas, ER, Hernandez, S, Futreal, A, Wargo, J, Schulze, K, Darbonne, WC, Ajami, NJ, Woodman, SE, de Groot, JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40289138.
3. Faraj, CA, McCutcheon, IE, Gubbiotti, M, Perni, S, Gule-Monroe, MK, Akdemir, KC, Clark, VE, Bander, ED, Loghin, ME, Prabhu, SS, Lang Jr, FF, Weinberg, J. Extra-central nervous system metastasis from high-grade glioma. Journal of neuro-oncology 173(1):193-204, 2025. e-Pub 2025. PMID: 40055259.
4. Lam, K, Nasr, L, Andersen, C, Marqueen, KE, Li, J, Wang, C, Beckham, TH, Majd, NK, Aaroe, AE, Loghin, ME, O'Brien, BJ, McGovern, SL. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Advances in Radiation Oncology 10(2), 2025. e-Pub 2025. PMID: 39866593.
5. Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O'Brien BJ, Majd NK, Loghin ME, Patel CB, Weathers SP, Puduvalli VK, Kamiya-Matsuoka C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study. Neurooncol Pract 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
6. Simbaqueba C, Aaroe A, Rubio D, Loghin ME, Treiber J, Ballester L, Fuller G, Gopakumar S, Kim B, Suarez-Almazor M. Leptomeningeal Immunoglobulin G4–Related Disease: A Case Report. AIM Clinical Cases 2(e230907), 2023. e-Pub 2023.
7. Robertson IJ, Gregory TA, Loghin ME. Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Annals of Case Reports(8):1331, 2023. e-Pub 2023.
8. Robertson IJ, Gregory TA, Loghin ME. Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Ann Case Report 8(3), 2023. e-Pub 2023.
9. Simbaqueba Clavijo, CA, Aaroe, AE, Rubio, D, Loghin, ME, Treiber, J, Ballester, L, Fuller, GN, Gopakumar, S, Kim, BY, Suarez-Almazor, M. Leptomeningeal Immunoglobulin G4–Related Disease. Annals of Internal Medicine Clinical Cases 2(12), 2023. e-Pub 2023.
10. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
11. Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. e-Pub 2022. PMID: 36128585.
12. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.

Review Articles

1. Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15:1447021, 2024. e-Pub 2024. PMID: 39247203.

Other Articles

1. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
2. Robertson IJ, Gregory TA, Loghin ME Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Annals of Case Reports, 2023.

Abstracts

1. Lam, K, Nasr, L, Andersen, C, Marqueen, K, Li, J, Wang, C, Majd, N, Aaroe, AE, Loghin ME, McGovern, S, O'Brien, BJ. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis from Solid Tumors. 29th Annual Meeting of the Society for Neuro-Oncology (SNO) 26(Suppl_8):viii74-viii75, 2024. e-Pub 2024.
2. Kamiya Matsuoka, C, Weathers, SP, Yung, A, Loghin ME, Majd, N, Brown, D, Langlands, J, Schwartz, R, Knight, S, Puduvalli, VK, de Groot, JF, O'Brien, BJ. Assessment of molecular alterations in newly diagnosed GBM MGMT-unmethylated patients treated with VAL-083. 29th Meeting of the Society for Neuro-Oncology (SNO) 26(Suppl_8):viii114, 2024. e-Pub 2024.
3. Majd N, Yeboa N, Weathers S, Robichaux C, Al Ansari H, Gachimova E, Loghin M, Kamiya Matsuoka C, O"Brien B, Aaroe A, Patel C, Yung A, Puduvalli V, de Groot J. Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma. Neuro-Oncology 25(Suppl_5):v84, 2023. e-Pub 2023.
4. Kamiya Matsuoka C, Weathers S, Yung A, Loghin M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, de Groot J, Puduvalli V, O'Brien B. Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM MGMT unmethylated patients. Neuro-Oncology 25(Suppl_5):v95-v96, 2023. e-Pub 2023.
5. Weathers S, Kamiya Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova, Aaroe A, Patel C, Loghin M, O'Brien B, Yung WKA, Puduvalli VK, de Groot J. Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Neuro-Oncology 25(Suppl_5):v67, 2023. e-Pub 2023.
6. Gottiparthy A, Orda-Nguyen L, Morrow E, Loghin ME. Outcomes of Patients with Neoplastic Meningitis Undergoing Ventriculoperitoneal Shunting and Intrathecal Chemotherapy. A single institution retrospective review. Poster Presentation, 2023 Annual Meeting of the American Academy of Neurology, 2023. e-Pub 2023.
7. Gregory T, Loghin M. Case report: extended remission of HER2-positive breast carcinoma with brain metastases and leptomeningeal disease following intrathecal and systemic trastuzumab. Neuro-Oncology 24(Suppl_7):vii198, 2022. e-Pub 2022.
8. Amer A, Darbandi AD, Wang EB, Ciavarra BN, Lano KR, Krayyem A, Alhasan HR, Fuller GR, Ferguson SD, Loghin ME, Li J, McGovern SL, Johnson JM. Clinical and pathologic characteristics of long-term glioblastoma survivors. 2022 ASCO Annual Meeting 40(Number 16_Suppl), 2022. e-Pub 2022.
9. Weathers SS, Zhu H, Knafl M, Damania A, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin ME, Penas-Prado M, Majd N, Yung WKA, O'Brien BJ, Wistuba II, Futreal A, Wargo JA, Ajami NJ, Woodman SE, de Groot JF. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. 2022 ASCO Annual Meeting 40(Number 16_Suppl), 2022. e-Pub 2022.
10. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, An S, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 23(Suppl_6):vi65, 2021. e-Pub 2021.
11. Weathers SP, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, Woodman S, de Groot J. Biomarker Immune Correlates in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Neuro-Oncology 23(Suppl_6):vi49, 2021. e-Pub 2021.
12. Weathers SP, Kamiya-Matsuoka C, Harrison R, Liu D, Sanqui, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, de Groot J. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 22((suppl 2)):ii35, 2020. e-Pub 2020.
13. Aaroe AA, Alfaro-Munoa KD, Bornstein C, Kell T, Camp S, Chen M, Woodman K, Tummala S, Kleiman A, de Groot JF, Loghin ME. A Retrospective Single-Center Experience with Nonbacterial Thrombotic Endocarditis and Stroke - Outcomes, Anticoagulation Strategies, and Incorporation of Next-Generation Sequencing Data. Neuro-Oncology 22((suppl 2)):ii127, 2020. e-Pub 2020.
14. Aaroe AA, Dono A, Youssef M, Alfaro-Munoz K, Weathers S, O’Brien BJ, Majd N, Harrison RA, Loghin ME, Soomro Z, Williford G, Fuller G, Yung WK, Yeboa D, Esquenazi, Ballester LY, de Groot JF, Kamiya Matsuoka C. A Retrospective Study of Treatment Strategies and Outcomes in WHO Grade II and III Isocitrate Dehydrogenase (IDH) Wild-Type Astrocytoma. Neuro-Oncology 22((suppl 2)):ii164-ii165, 2020. e-Pub 2020.
15. Aaroe A, Team D, Harrison R, Majd N, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, de Groot J, Woodman K. A Snapshot of the Impact of COVID-19 on Patients with Nervous System Tumors. Neuro-Oncology 22((suppl 2)):ii27, 2020. e-Pub 2020.
16. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 22((suppl 2)):ii59, 2020. e-Pub 2020.
17. Youssef MN, Pham LC, Demirhan M, Harrison RA, Loghin ME, Johnson JK, Alfaro-Munoz KD, Bhat KP, Yeboa D, Prabhu SS, Raza S, de gRoot JF, Demonte F, Kamiya-Matsuoka C. Long-Term Use of Everolimus plus Octreotide for Recurrent Intracranial or Spinal Meningioma: A Single Institution Experience. Neuro-Oncology 22((suppl 2)):ii55, 2020. e-Pub 2020.
18. Weathers S, Kamiya Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd N, Yung WK, O’Brian BJ, de Groot JF. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Journal of Clinical Oncology 38(suppl_15), 2020. e-Pub 2020.
19. O'Brien B, Penas-Prado M, Kamiya C, Weathers SP, Yung WK, Loghin M, Harrison RA, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro-Oncology 21(suppl_6):vi14-vi15, 2019. e-Pub 2019.
20. Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro-Oncology Advances 1(suppl_1):i8, 2019. e-Pub 2019.
21. Kamiya Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline Mutations?. Annals of Oncology 30(suppl_5):v143-v158, 2019. e-Pub 2019.
22. Weathers S, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O'Brien B, Harrison R, Yung WK, Penas-Prado M, de Groot J. Safety Run-In Results for a Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 20(suppl_6):vi9–vi10, 2018. e-Pub 2018.
23. de Groot J, Penas-Prado M, Mandel J, O'Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse J, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger A. Window-of-Opportunity Clinical Trial of Pembrolizumab in Recurrent Glioblastoma Patients. Neuro-Oncology 20(suppl_6):vi2, 2018. e-Pub 2018.
24. Penas-Prado M, Weathers S, Zhou S, Kamiya-Matsuoka C, O'Brien B, Loghin M, Harrison R, Pei B, Ictech S, Hunter K, Yung WK, de Groot J, Shpall EJ, Heimberger A, Rezvani K. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro-Oncology 20(suppl_6):vi2–vi3, 2018. e-Pub 2018.
25. Metrus N, Daher A, Harrison R, Majd N, Maraka S, Nam J, Trevino C, Weathers S, O'Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WK, de Groot J, Penas-Prado M. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro-Oncology 20(suppl_6):vi141, 2018. e-Pub 2018.
26. Kamiya Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, Weathers, SS, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison, RA, Yung, WK, Meric-Bernstam F, Groot D, JF. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(suppl), 2018. e-Pub 2018.

Book Chapters

1. Majd NK, Loghin M. Leptomeningeal Disease in Solid Cancers. In: Oncologic Critical Care. Springer, Cham, 2019.
2. Loghin M, Kleiman A. Medication-Induced Neurotoxicity in Critically Ill Cancer Patients. In: Oncologic Critical Care. Springer, Cham, 2019.